Supplementary Figure S3 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT | Synapse
August 1, 2024Open Access
Supplementary Figure S3 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
Puntos clave
Los puntos clave no están disponibles para este artículo en este momento.
Resumen
Correlation between MGMT mRNA and MGTM protein abundance values in glioblastoma from the CPTAC database.